Clarus Ventures
-
Buoyed by Drug to Fight Radiation Sickness in Cancer Patients, Malvern’s Galera Therapeutics Goes Public
At $12 a share, Malvern-based Galera Therapeutics raised $60 million in its initial public offering and is now trading under the GRTX symbol on the…
Pioneer Partner
Founding Partners
Advertisement
Affiliate Partners
Community Partners
